BRPI0517668A - formulação lipossÈmica de ácidos borÈnicos de peptìdeo - Google Patents

formulação lipossÈmica de ácidos borÈnicos de peptìdeo

Info

Publication number
BRPI0517668A
BRPI0517668A BRPI0517668-9A BRPI0517668A BRPI0517668A BR PI0517668 A BRPI0517668 A BR PI0517668A BR PI0517668 A BRPI0517668 A BR PI0517668A BR PI0517668 A BRPI0517668 A BR PI0517668A
Authority
BR
Brazil
Prior art keywords
liposome
peptide boronic
captured
boronic acids
liposomal formulation
Prior art date
Application number
BRPI0517668-9A
Other languages
English (en)
Inventor
Samuel Zalipsky
Francis Martin
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0517668A publication Critical patent/BRPI0517668A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAçãO LIPOSSÈMICA DE áCIDOS BORÈNICOS DE PEPTìDEO. A presente invenção refere-se a uma composição de lipossoma que compreende lipossomas tendo um composto inibidor de proteassoma de ácido borónico de peptídeo capturado no lipossoma. O composto de ácido borónico é capturado no lipossoma na forma de um éster de boronato, subseqüente à interação com um poliol capturado no lipossoma. Em uma modalidade, os lipossomas têm um revestimento externo de cadeias de polímero hidrofílico e são usados para tratar uma malignidade em um indivíduo.
BRPI0517668-9A 2004-11-05 2005-11-04 formulação lipossÈmica de ácidos borÈnicos de peptìdeo BRPI0517668A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62521604P 2004-11-05 2004-11-05
PCT/US2005/039973 WO2006052734A1 (en) 2004-11-05 2005-11-04 Liposome formulation of peptide boronic acids compounds

Publications (1)

Publication Number Publication Date
BRPI0517668A true BRPI0517668A (pt) 2008-10-14

Family

ID=35947260

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0517061-3A BRPI0517061A (pt) 2004-11-05 2005-11-04 formulação lipossomal de bortezomib (ps-341)
BRPI0517668-9A BRPI0517668A (pt) 2004-11-05 2005-11-04 formulação lipossÈmica de ácidos borÈnicos de peptìdeo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0517061-3A BRPI0517061A (pt) 2004-11-05 2005-11-04 formulação lipossomal de bortezomib (ps-341)

Country Status (21)

Country Link
US (2) US20060159736A1 (pt)
EP (2) EP1807052A1 (pt)
JP (2) JP2008519041A (pt)
KR (2) KR20070085644A (pt)
CN (2) CN101094648A (pt)
AR (1) AR051759A1 (pt)
AU (2) AU2005304881A1 (pt)
BR (2) BRPI0517061A (pt)
CA (2) CA2586354A1 (pt)
CR (1) CR9168A (pt)
EA (1) EA200701005A1 (pt)
IL (1) IL182967A0 (pt)
MX (2) MX2007005499A (pt)
NI (1) NI200700120A (pt)
NO (1) NO20072830L (pt)
NZ (2) NZ554950A (pt)
PE (1) PE20061135A1 (pt)
TW (1) TW200618820A (pt)
UY (1) UY29191A1 (pt)
WO (2) WO2006052734A1 (pt)
ZA (1) ZA200705017B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
WO2009047639A2 (en) * 2007-07-23 2009-04-16 Keimyung University Industry Academic Cooperation Foundation Epicatechin deficient green tea
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
MY161991A (en) * 2007-08-06 2017-05-31 Millennium Pharm Inc Proteasome inhibitors
KR20100095507A (ko) * 2007-08-21 2010-08-31 알자 코퍼레이션 보론산 화합물의 생체내 투여를 위한 리포좀 조성물
MX2010002101A (es) * 2007-08-21 2010-03-26 Alza Corp Formulaciones de liposomas de compuestos de acido boronico.
MX2010013642A (es) 2008-06-17 2010-12-21 Millennium Pharm Inc Compuestos de ester boronato y composiciones farmaceuticas de los mismos.
KR100918776B1 (ko) * 2009-04-20 2009-09-24 계명대학교 산학협력단 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물
JP5848127B2 (ja) 2008-08-13 2016-01-27 カリフォルニア インスティテュート オブ テクノロジー 担体ナノ粒子ならびに関連する組成物、方法およびシステム
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
RU2529800C2 (ru) * 2010-03-18 2014-09-27 ИННОФАРМА, Инк. Стабильные составы бортезомиба
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
IT1403157B1 (it) 2010-12-01 2013-10-04 Elbi Int Spa Macchina lavatrice con rilevazione delle vibrazioni della vasca o camera di lavaggio.
AU2012223210B2 (en) * 2011-03-02 2016-12-22 Board Of Regents Of The University Of Texas System Vesicle compositions
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
AU2013360302C1 (en) 2012-12-12 2019-01-24 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2015002078A1 (ja) 2013-07-03 2015-01-08 日本化薬株式会社 ボロン酸化合物の新規製剤
CN111116622A (zh) * 2014-02-03 2020-05-08 俄亥俄州创新基金会 硼酸酯和其药物制剂
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
KR102509950B1 (ko) 2014-05-20 2023-03-14 밀레니엄 파머슈티컬스 인코퍼레이티드 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6715265B2 (ja) * 2015-05-04 2020-07-01 フェルザンティス アーゲーＶｅｒｓａｎｔｉｓ Ａｇ 膜内外ｐＨ勾配ベシクルを調製する方法
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
CN104958768A (zh) * 2015-07-17 2015-10-07 中国科学院长春应用化学研究所 一种葡聚糖-硼替佐米键合药及其制备方法
US11135309B2 (en) * 2015-08-14 2021-10-05 The Regents Of The University Of California Poly(vinyl alcohol) nanocarriers
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10583083B1 (en) * 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
WO2018073790A1 (en) 2016-10-20 2018-04-26 Pfizer Inc. Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same
US11964050B2 (en) * 2017-07-24 2024-04-23 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
IL273551B2 (en) 2017-10-11 2024-02-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis
CN110540547A (zh) 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
CN109045272A (zh) * 2018-08-01 2018-12-21 厦门市壳聚糖生物科技有限公司 一种硼替佐米磷脂复合物及其制备方法与应用
EP4041246A4 (en) * 2019-10-07 2023-11-01 Cornell University ANTIMICROBIAL AND ANTIVIRAL EFFECTS OF ALKYL-BORONIC ACIDS C2-C7
US20240173374A1 (en) * 2021-02-25 2024-05-30 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN112915094A (zh) * 2021-03-26 2021-06-08 东南大学 一种硼替佐米脂质体制剂的制备方法
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5047245A (en) * 1985-07-26 1991-09-10 The Liposome Company, Inc. Novel composition for targeting, storing and loading of liposomes
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
AU660288B2 (en) * 1990-07-31 1995-06-22 Transave, Inc. Accumulation of amino acids and peptides into liposomes
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
WO1998017256A1 (en) * 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6051251A (en) * 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
KR100679906B1 (ko) * 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
CA2379060A1 (en) * 1999-07-14 2001-01-25 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
AU1658401A (en) * 1999-11-19 2001-05-30 Topgene, Inc. Boron compounds and complexes as anti-inflammatory agents
EP3078667B1 (en) * 2001-01-25 2018-11-21 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
CA2504933C (en) * 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors

Also Published As

Publication number Publication date
KR20070085642A (ko) 2007-08-27
MX2007005497A (es) 2007-09-21
WO2006052734A1 (en) 2006-05-18
CN101094649A (zh) 2007-12-26
UY29191A1 (es) 2006-01-31
CN101094648A (zh) 2007-12-26
NZ554950A (en) 2010-12-24
US20060159736A1 (en) 2006-07-20
AU2005304880A1 (en) 2006-05-18
NZ554951A (en) 2010-12-24
EA200701005A1 (ru) 2007-10-26
AR051759A1 (es) 2007-02-07
BRPI0517061A (pt) 2008-09-30
EP1807053A1 (en) 2007-07-18
AU2005304881A1 (en) 2006-05-18
CA2586348A1 (en) 2006-05-18
JP2008519041A (ja) 2008-06-05
KR20070085644A (ko) 2007-08-27
JP2008519040A (ja) 2008-06-05
NI200700120A (es) 2008-05-15
EP1807052A1 (en) 2007-07-18
WO2006052733A1 (en) 2006-05-18
ZA200705017B (en) 2008-09-25
NO20072830L (no) 2007-07-24
IL182967A0 (en) 2007-08-19
TW200618820A (en) 2006-06-16
PE20061135A1 (es) 2006-10-20
CA2586354A1 (en) 2006-05-18
US20060153907A1 (en) 2006-07-13
CR9168A (es) 2008-11-24
MX2007005499A (es) 2007-09-21

Similar Documents

Publication Publication Date Title
BRPI0517668A (pt) formulação lipossÈmica de ácidos borÈnicos de peptìdeo
CL2012003229A1 (es) Formulación farmacéutica para aplicación tópica en la piel que comprende una emulsión de aceite en agua y el compuesto (r)-3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrilo, inhibidor de jak1/jak2; método para tratar un trastorno de la piel; y su uso en el tratamiento de un trastorno de la piel.
ECSP109983A (es) Formulaciones de liposomas de compuestos de acido boronico
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CR20110324A (es) ANTICUERPO ANTI-cMET NOVEDOSO
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
ATE411006T1 (de) Liposomale anordnung für die therapeutische und/oder diagnostische anwendung
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP2664321A3 (en) Medical instrument
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
BRPI0408490A (pt) composições que compreendem ácidos graxos e aminoácidos
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
ECSP088889A (es) Forma nueva de administración de racecadotril
ECSP066970A (es) Preparaciones tópicas que contienen ambroxol
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
WO2004087072A3 (en) Topical l-carnitine compositions
BR112015015371A2 (pt) realçador de aparência para composições de borracha com antidegradantes
NI201000047A (es) Uso de 3, 11b-cis-dihidrotetrabenzina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
CY1108869T1 (el) Φωτοσταθεροποιημενα τοπικα σκευασματα κετοπροφαινης που περιεχουν δυο φιλτρα uv
BR112014013878A2 (pt) emplastro
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora
DK1480625T3 (da) Transdermalt system med fentanyl

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2209 DE 07/05/2013.